Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

Conditions

• CANCER, NOS

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Lirilumab — DRUG
• Ipilimumab — DRUG

Study Details

To assess the safety and tolerability, characterize the dose-limiting toxicities (DLTs), and identify the maximally tolerated dose (MTD) of BMS-986015 given in combination with ipilimumab in subjects with select advanced (metastatic and/or unresectable) solid tumors.

Key Dates

Start date

Dec 31, 2012

Status verified

Jul 2015

Primary completion

Apr 30, 2015

Completion

Apr 30, 2015

Study Design

Enrollment

22 participants (actual)

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Arm 1: Lirilumab + Ipilimumab
  Lirilumab and Ipilimumab on specific days

Primary Outcome Measure

Safety as measured by the rate of adverse events, and serious adverse events [ Time Frame: Approximately 510 days ]

Locations (6)

Find similar trials in Tampa, FL